GlassScriptPhysician profile
Johnnie Carter
NPI 1558458257
$2,661.72
in general payments reported to CMS, 2019-2025
28 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $597 · 2021: $584 · 2022: $166 · 2023: $354 · 2024: $414 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,079.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $497.90 | 2019-2025 | |
| Novo Nordisk INC | $417.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $407.69 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $302.55 | 2021-2025 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $188.77 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $127.74 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $98.64 | 2020-2025 | Rexulti |
| Arbor Pharmaceuticals, INC. | $65.30 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.11 | 2022-2024 | |
| Exact Sciences Corporation | $54.92 | 2023-2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $53.37 | 2024-2025 | Auvelity |
| Allergan, INC. | $52.77 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.48 | 2022 | |
| Merck Sharp & Dohme LLC | $38.91 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $30.51 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.16 | 2020-2021 | |
| Glaxosmithkline, LLC. | $23.35 | 2023 | Arexvy, Shingrix |
| Lundbeck LLC | $19.78 | 2024 | Rexulti |
| Evoke Pharma, INC. | $19.33 | 2023 | Gimoti |
| Medtronic, INC. | $18.74 | 2021 | |
| Shield Therapeutics INC | $17.61 | 2023 | Accrufer |
| Esperion Therapeutics, INC. | $16.53 | 2020 | |
| Sumitomo Pharma America, INC. | $15.43 | 2023 | Gemtesa |
| Paratek Pharmaceuticals, INC. | $14.30 | 2023 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $14.21 | 2022 | |
| Shire North American Group INC | $12.70 | 2019 | |
| Eisai INC. | $12.41 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnnie Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.